Results 101 to 110 of about 12,926,306 (256)
Frontiers in ImmunologyAlveolar echinococcosis (AE) is a zoonotic parasitic disease caused by the infection of Echinococcus multilocularis (E. multilocularis) larvae. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) produces inhibitory signals and induces T cell exhaustion, thereby ...
Yuxuan Yang +8 more
doaj +1 more source
PLoS ONE, 2015 The immune suppressive protein CTLA-4 is constitutively expressed by Tregs and induced in effector T cells upon activation. Its crucial role in adaptive immunity is apparent from the fatal autoimmune pathology seen in CTLA-4 knockout mice.
Louisa E Jeffery +8 more
doaj +1 more source
The cytoplasmic tail of CTLA-4 is dispensable for Nef-induced CTLA-4 down-regulation.
, 2013 a) Accumulation of CTLA-4 on the cell surface after transfection with CTLA-4 Y201AY218G and CTLA-4ΔCT mutants and lower expression after transfection with CTLA-4 LL181AA. Black solid histograms represent the isotype controls.
Rabih Halwani (287270) +14 more
core +1 more source
BMEMat, EarlyView.Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen +9 more
wiley +1 more source
Therapeutic Advances in Medical OncologyBackground: CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents.
Nithya Krishnamurthy +9 more
doaj +1 more source
Fatal CTLA‐4 heterozygosity with autoimmunity and recurrent infections: a de novo mutation
Clinical Case Reports, 2017 Key Clinical Message Primary immunodeficiency disorders are rarely diagnosed in adults but must be considered in the differential diagnosis of combined recurrent infections and autoimmune disease.
Maria Francisca Moraes‐Fontes +9 more
doaj +1 more source
Chronic Diseases and Translational Medicine, EarlyView.PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi +2 more
wiley +1 more source
Cytometry Part A, EarlyView.ABSTRACT Peripheral blood mononuclear cells (PBMCs) are commonly used for immune profiling in clinical research, but their isolation and cryopreservation present logistical challenges, particularly in settings with limited access to research facilities. To address this, we implemented a whole blood fixation protocol to preserve surface protein epitopes
Vaishnavi Parthasarathy +8 more
wiley +1 more source
Head &Neck, EarlyView.ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
Degradation of CTLA-4 chimeras.
, 2013 A. CHO cells expressing CTLA-4 chimeras were incubated in medium or medium supplemented with cycloheximide (CHX) at 37°C for 3 hours. Cells were fixed, permeabilised and stained for total CTLA-4 with an unlabeled anti-CTLA-4 Ab followed by Alexa488 anti ...
Satdip Kaur (397530) +2 more
core +1 more source